Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956798 · ClinicalTrials.gov registry record · Phase 2
SAbR For Oligometastatic Renal Cell Carcinoma
A Phase 2 study of Oligometastatic Renal Cell Carcinoma, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT02956798 is a Phase 2 study of Oligometastatic Renal Cell Carcinoma that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 23 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02956798, a Phase 2 study of Oligometastatic Renal Cell Carcinoma, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis: Stereotactic ablative body radiation (SAbR) prolongs progression-free survival for patients with oligometastatic kidney cancer (RCC) and delays the initiation of systemic therapy. Primary Objectives: • To evaluate the delay in time to start of systemic therapy (TTST) as a surrogate of progression free survival (PFS), defined as the time from the first day of SAbR to start of systemic therapy. Secondary Objective: * To evaluate the modified progression-free survival (mPFS) for patients with oligometastatic renal cell carcinoma who are treated with SAbR. * To evaluate the overall survival (OS) * To evaluate the cancer specific survival (CSS) * To evaluate the local control rate of irradiated lesions. * To measure the health-related quality of life (HRQOL).
Conditions Studied
Interventions
- RADIATION Stereotactic ablative body radiation (SABR)
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956798
The ClinicalTrials.gov registry entry for NCT02956798 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oligometastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic ablative body radiation (SABR) is the first listed.
NCT02956798 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02956798 about?
NCT02956798 is a clinical study titled "SAbR For Oligometastatic Renal Cell Carcinoma". Hypothesis: Stereotactic ablative body radiation (SAbR) prolongs progression-free survival for patients with oligometastatic kidney cancer (RCC) and delays the initiation of systemic therapy. Primary Objectives: • To evaluate the delay in time to start of systemic therapy (TTST) as a surrogate of...
What is the current status of trial NCT02956798?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-07-19. Estimated completion is 2025-12-31.
What conditions does trial NCT02956798 study?
This clinical trial studies the following conditions: Oligometastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT02956798?
The interventions under investigation include: Stereotactic ablative body radiation (SABR) (RADIATION).
Who is sponsoring clinical trial NCT02956798?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02956798 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oligometastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.